Bushra Salman

Mrs. Bushra Salman


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2025 in Genes
Verified
Journal Article
Open access
PDF file
NANahad Mohammed Al-Mahrouqi
Nahad Mohammed Al-Mahrouqi
NSNada Al Shuaili
Nada Al Shuaili
SAShoaib Al-Zadjali
Shoaib Al-Zadjali
APAnoopa Pullanhi
Anoopa Pullanhi
HAHamida Al-Barwani
Hamida Al-Barwani
BSBushra Salman
Bushra Salman
Background/Objectives: Pharmacogenomic screening plays a crucial role in optimizing chemotherapy outcomes and minimizing toxicity. Characterizing the baseline distribution of genetic variants in specific populations is essential to inform the prioritization of drug–gene combinations for clinical implementation. The objective of this study was to investigate the distribution of pharmacogenetic variants in 36 genes related to the fluoropyrimidine (FP) pathway among healthy Omani individuals, forming a foundation for future studies in cancer patients receiving FP-based chemotherapy. Methods: Ninety-eight healthy Omani participants aged ≥18 years were recruited at the Sultan Qaboos Comprehensive Cancer Care and Research Center. Whole-blood samples were collected, and genomic DNA was extracted. Targeted next-generation sequencing was performed using a custom Ion AmpliSeq panel covering coding exons and splice-site regions of 36 genes involved in FP metabolism and response. Results: A total of 999 variants were detected across the 36 genes, with 63.3% being heterozygous. The ABCC4 gene had the highest mutation frequency (76 mutations), while DHFR and SMUG1 had the lowest (<10 mutations). In DPYD, four functionally significant variants were found at frequencies ranging from 1 to 8.2% of the population. Missense mutations were also observed in MTHFR and UGT1A1. Three actionable variants in DPYD and MTHFR, associated with 5-fluorouracil and/or capecitabine response, were identified. Additionally, 27 novel single-nucleotide polymorphisms of unknown clinical significance were detected. Conclusions: This study reveals key pharmacogenetic variants in the Omani population, underscoring the importance of integrating pharmacogenomic testing into routine care to support safer, more personalized chemotherapy in the region.

30 July 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
NANashwa Al-Sharji
Nashwa Al-Sharji
BSBushra Salman
Bushra Salman
SAShireen Al-Zadjali
Shireen Al-Zadjali
MAMohammed Al-Huneini
Mohammed Al-Huneini
Background: Chronic immune thrombocytopenia (ITP) is characterized by persistent thrombocytopenia and bleeding risk, and a subset of patients remains refractory or relapses despite multiple lines of therapy. Avatrombopag is an oral thrombopoietin receptor agonist approved for adults with chronic ITP with insufficient response to prior treatment. We descrixbe a real-world single-center experience with avatrombopag in Oman. Methods: We conducted a retrospective case series of consecutive adults with chronic primary ITP treated with avatrombopag at a tertiary care center in Muscat, Oman. Patients initiated avatrombopag between September 2023 and June 2025 and were followed through October 2025. Platelet counts, treatment patterns, transfusion requirements, corticosteroid use, rescue therapies, and adverse drug reactions (ADRs) were abstracted from electronic medical records. Results: Twelve heavily pretreated patients were included, with a median baseline platelet count of 14.5 × 10 9 /L (IQR 4.8–28.8). Eleven patients (91.7%) started avatrombopag at 20 mg once daily, and one patient (8.3%) started at 20 mg on alternate days; 66.7% required subsequent dose adjustment. Overall, 75.0% achieved platelet counts ≥ 50 × 10 9 /L at least once during follow-up, with a median platelet count of 160 × 10 9 /L at month 3 and 98 × 10 9 /L at the most recent assessment. Transfusion burden improved in 60% of patients with high baseline transfusion requirements. Steroid-sparing was observed in 83.3, and 66.7% were steroid-free during follow-up. ADRs occurred in 33.3% (primarily body pain and rash); no hepatotoxicity or treatment discontinuation due to ADRs was documented. Conclusion: In chronic, heavily pretreated ITP, avatrombopag was associated with clinically meaningful platelet responses, substantial steroid-sparing, and an acceptable tolerability profile.

17 April 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
BSBushra Salman
Bushra Salman
IYIntissar Yehia
Intissar Yehia
HSHadil Sulaiman Al sharqi
Hadil Sulaiman Al sharqi
RSRoula Al Shidi
Roula Al Shidi
MDMiaad A. Al Dhahri
Miaad A. Al Dhahri
KAKhalid Al-Baimani
Khalid Al-Baimani
Objectives: To evaluate the association between European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) scores and treatment recommendations from European Society for Medical Oncology, National Comprehensive Cancer Network (NCCN), and American Society of Clinical Oncology (ASCO) in curative and metastatic breast cancer (BC), and to assess inter-guideline concordance. Methods: We conducted a comparative review of 47 systemic BC therapies with published ESMO-MCBS scores (accessed 30 June 2025). Guideline recommendations from ESMO, NCCN, and ASCO were extracted from the most recent versions and harmonized into ordinal tiers. Associations between MCBS scores and recommendation categories were evaluated using Fisher’s exact test and Spearman’s rank correlation in the palliative setting. Curative therapies were analyzed descriptively due to limited variability. Results: Among 38 palliative therapies, 40% achieved high clinical benefit (MCBS 4–5). A significant association was observed between MCBS scores and NCCN recommendations (p = 0.003; ρ = 0.48), with 62% of NCCN Category 1 therapies demonstrating high benefit versus 13% in other categories. No significant associations were observed with ASCO (p = 0.101; ρ = 0.18) or ESMO guideline recommendations (p = 0.073; ρ = 0.19). Inter-guideline concordance was strongest between ASCO and ESMO (p = 0.033; ρ = 0.48). In the curative setting (n = 9), most therapies received an MCBS grade A and top-tier guideline endorsement. Conclusions: Alignment between ESMO-MCBS and guideline recommendations is moderate and framework-dependent, strongest with NCCN in metastatic BC. Discordance primarily reflects differences between magnitude-of-benefit thresholds and evidence-certainty frameworks. ESMO-MCBS may serve as a complementary tool to enhance value-based clinical and policy decision-making.

8 November 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
AMAmna Mohamed
Amna Mohamed
JAJokha Hamed Hilal Al-Qassabi
Jokha Hamed Hilal Al-Qassabi
BSBushra Salman
Bushra Salman
Khaled AbduljalilKhaled Abduljalil
Khaled Abduljalil
Background: Hydroxyurea is the cornerstone disease-modifying therapy for sickle cell disease (SCD), but interindividual pharmacokinetic (PK) variability contributes to differences in drug exposure and treatment response. This scoping review synthesised evidence on hydroxyurea PK, pharmacodynamic (PD) relationships, determinants of exposure, pharmacometric modelling, and precision dosing approaches in SCD. Methods: A scoping review was conducted according to PRISMA-ScR guidance. Studies involving paediatric or adult patients with SCD that evaluated hydroxyurea PK, PK-PD relationships, exposure determinants, pharmacometric modelling, or PK-guided dosing were included. Study characteristics, PK parameters, covariates, modelling approaches, and key findings were charted and synthesised descriptively. Results: Twenty-seven studies published between 2005 and 2026 were included. Hydroxyurea demonstrated rapid oral absorption (Tmax 0.73–1.7 h), a short elimination half-life (1.7–2.9 h), and variability in systemic exposure across individuals (coefficient of variation approximately 40–45%). Body weight and renal function were the most consistently identified determinants of disposition, with renal impairment associated with reduced clearance and increased exposure. PK of hydroxyurea were well described by population PK and physiologically based PK models. PK-guided dosing showed potential to shorten the time to maximum tolerated dose and improve haematological responses. However, exposure–response and exposure–toxicity relationships remain insufficiently characterised, and evidence directly linking hydroxyurea exposure to patient-centred clinical outcomes was limited. Conclusions: Pharmacometric modelling and model-informed precision dosing (MIPD) have potential to support individualised hydroxyurea therapy, particularly in paediatric patients and those with altered renal function. Prospective external validation across diverse paediatric and adult populations, together with validated exposure–response and exposure–toxicity targets and clinically meaningful efficacy and safety outcomes, is required before routine clinical application can be recommended.

Verified
Journal Article
Open access
PDF file
NSNajah abdullah Salmi
Najah abdullah Salmi
BSBushra Salman
Bushra Salman
YKYaman Walid Kassab
Yaman Walid Kassab
SZShireen Imam Bakhsh Al Zadjali
Shireen Imam Bakhsh Al Zadjali
MBMULLAICHARAM BHUPATHYRAAJ
MULLAICHARAM BHUPATHYRAAJ
Salam AlKindiSalam AlKindi
Salam AlKindi
Background: Myeloproliferative neoplasms (MPNs)—including primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET)—are clonal stem-cell disorders driven by JAK–STAT pathway activation within an inflammatory microenvironment. Ruxolitinib (RUX), a JAK1/2 inhibitor, improves splenomegaly and symptom burden in myelofibrosis and serves as second-line therapy in hydroxyurea-resistant/intolerant PV. However, real-world data from Middle Eastern populations remains scarce. This study evaluates the effectiveness, safety, and dosing practices of RUX in a heterogeneous Omani MPN cohort. Methods: Electronic records were reviewed for adults diagnosed with MF, PV, or ET who received RUX at Sultan Qaboos University Hospital or the National Hematology and BMT Center between 2018 and 2025. Only patients with at least six months of follow-up were included. Clinical variables, laboratory results, dosing information, and data on treatment responses and toxicities were extracted. Outcomes focused on spleen size changes, symptom improvement, hematologic responses, adverse events, and reasons for treatment discontinuation. Results: Twenty-eight patients were included (71% PMF; mean age 52.6 years). The median time from diagnosis to RUX initiation was 28 months. Among MF patients, mean spleen size decreased by 35% (p = 0.003); 28% achieved ≥35% reduction. Symptomatic improvement was reported by 60%. LDH levels remained unchanged. PV patients showed spleen control in 75% and symptom benefit in all cases, while ET responses were limited. Cytopenias (21%) and infections (11%) were the most common toxicities; discontinuation occurred in 8/28 of patients, and two patients died while on therapy. Initial dosing was frequently inappropriate, particularly underdosing in MF and overdosing in PV. Conclusions: RUX provided meaningful spleen and symptom improvement in MF and PV; however, toxicity, delayed initiation, and inconsistent dosing practices limited overall outcomes. Enhanced guideline-based dosing, proactive toxicity management, and structured multidisciplinary follow-up are essential to optimize RUX use in regional MPN practice.

15 July 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
NANoor Al-Rawahi
Noor Al-Rawahi
BSBushra Salman
Bushra Salman
DMDhanalekshmi Unnikrishnan Meenakshi
Dhanalekshmi Unnikrishnan Meenakshi
MAMurtadha Al-Khabori
Murtadha Al-Khabori
MAMohammed Al-Hanini
Mohammed Al-Hanini
SASalam Al-Kindi
Salam Al-Kindi
Background: Real-world data on tyrosine kinase inhibitor (TKI) use in chronic myeloid leukemia (CML) from the Middle East remain limited. We evaluated treatment patterns, molecular responses, treatment-free remission (TFR), and safety among Omani patients with chronic-phase CML. Methods: In this retrospective single-center study, adult patients (≥18 years) with chronic-phase CML treated with TKIs between January 2008 and September 2024 were included. Demographics, Sokal risk, treatment lines, molecular responses, TFR, and adverse drug reactions (ADRs) were analyzed. Results: Among 112 patients (mean age 43.7 ± 15.4 years), 45% had low Sokal risk, 43% intermediate, and 12% high risk. Imatinib was first-line therapy in 88.4%, achieving major molecular response (MMR) in 51%, with a median time to MMR of 21 months. In contrast, second-line TKIs demonstrated higher efficacy, with MMR rates of 79.2% for nilotinib and 54.4% for dasatinib, and shorter time to response (12 vs 23.2 months, respectively). Successful TFR was maintained in 17% of imatinib-treated patients after two years and in 83.3% of second-line patients after 36 months. ADRs were mainly gastrointestinal (28.5%), musculoskeletal (28.0%), dermatologic (20.8%), and hematologic (8.7%). Grade 3–4 events occurred in 5%, leading to TKI switching. Discontinuations were primarily due to loss of response, ADRs, or planned TFR. Conclusion: In this real-world cohort, first-line imatinib provided acceptable but slower and less frequent molecular responses compared with second-generation TKIs. Higher TFR maintenance rates were observed with second-generation TKIs, although interpretation is limited by small patient numbers. These findings support a response-guided, risk-adapted approach to TKI selection and highlight the need to expand access to second-generation TKIs to optimize long-term outcomes in CML.